Development of a topically active imiquimod formulation
- Author
- CHOLLET, J. L1 ; JOZWIAKOWSKI, M. J2 ; PHARES, K. R2 ; REITER, M. J3 ; RODDY, P. J2 ; SCHULTZ, H. J4 ; TA, Q. V2 ; TOMAI, M. A3
[1] Analytical Research and Development, 3M Pharmaceuticals, St. Paul, Minnesota, United States
[2] Conventional Drug Delivery, 3M Pharmaceuticals, St. Paul, Minnesota, United States
[3] Pharmacology Department, 3M Pharmaceuticals, St. Paul, Minnesota, United States
[4] Transdermal Drug Delivery, 3M Pharmaceuticals, St. Paul, Minnesota, United States - Source
Pharmaceutical development and technology. 1999, Vol 4, Num 1, pp 35-43 ; ref : 14 ref
- ISSN
- 1083-7450
- Scientific domain
- Pharmacology drugs
- Publisher
- Informa Healthcare, New York, NY
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Animal Effet biologique Emulsion huile eau Excipient Forme pharmaceutique Imiquimod Immunomodulateur In vitro In vivo Libération Peau glabre Solubilité Souris Stabilisant Stéarique acide Système administration Technologie pharmaceutique Voie externe Mammalia Rodentia Vertebrata
- Keyword (en)
- Animal Biological effect Oil water emulsion Vehicle(excipient) Dosage form Imiquimod Immunomodulator In vitro In vivo Release Glabrous skin Solubility Mouse Stabilizer agent Stearic acid Delivery system Pharmaceutical technology Topical administration Mammalia Rodentia Vertebrata
- Keyword (es)
- Animal Efecto biológico Emulsión aceite agua Excipiente(vehiculo) Forma farmacéutica Imiquimod Inmunomodulador In vitro In vivo Liberación Piel lampiña Solubilidad Ratón Estabilizante Esteárico ácido Sistema administración Tecnología farmacéutica Vía externa Mammalia Rodentia Vertebrata
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02A General pharmacology / 002B02A03 Pharmaceutical technology. Pharmaceutical industry
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02Q Immunomodulators
- Discipline
- General pharmacology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 1686448
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1080/10837459908984222 
https://dx.doi.org/10.1080/10837459908984222
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1080\/10837459908984222\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:55:\"Development of a topically active imiquimod formulation\";s:9:\"\u0000*\u0000jtitle\";s:41:\"Pharmaceutical development and technology\";s:9:\"\u0000*\u0000stitle\";s:19:\"Pharm. dev. technol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:1:\"4\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"35\";s:8:\"\u0000*\u0000epage\";s:2:\"43\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1083-7450\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"CHOLLET\";s:10:\"\u0000*\u0000aufirst\";s:4:\"J. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:18:\"JOZWIAKOWSKI, M. J\";i:1;s:12:\"PHARES, K. R\";i:2;s:12:\"REITER, M. J\";i:3;s:11:\"RODDY, P. J\";i:4;s:13:\"SCHULTZ, H. J\";i:5;s:8:\"TA, Q. V\";i:6;s:11:\"TOMAI, M. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:55:\"Development of a topically active imiquimod formulation\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Informa Healthcare\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1080\/10837459908984222\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:55:\"Development of a topically active imiquimod formulation\";s:9:\"\u0000*\u0000jtitle\";s:41:\"Pharmaceutical development and technology\";s:9:\"\u0000*\u0000stitle\";s:19:\"Pharm. dev. technol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:1:\"4\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"35\";s:8:\"\u0000*\u0000epage\";s:2:\"43\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1083-7450\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"CHOLLET\";s:10:\"\u0000*\u0000aufirst\";s:4:\"J. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:18:\"JOZWIAKOWSKI, M. J\";i:1;s:12:\"PHARES, K. R\";i:2;s:12:\"REITER, M. J\";i:3;s:11:\"RODDY, P. J\";i:4;s:13:\"SCHULTZ, H. J\";i:5;s:8:\"TA, Q. V\";i:6;s:11:\"TOMAI, M. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:55:\"Development of a topically active imiquimod formulation\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Informa Healthcare\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1080\/10837459908984222\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1080\/10837459908984222\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:55:\"Development of a topically active imiquimod formulation\";s:9:\"\u0000*\u0000jtitle\";s:41:\"Pharmaceutical development and technology\";s:9:\"\u0000*\u0000stitle\";s:19:\"Pharm. dev. technol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:1:\"4\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"35\";s:8:\"\u0000*\u0000epage\";s:2:\"43\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1083-7450\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"CHOLLET\";s:10:\"\u0000*\u0000aufirst\";s:4:\"J. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:18:\"JOZWIAKOWSKI, M. J\";i:1;s:12:\"PHARES, K. R\";i:2;s:12:\"REITER, M. J\";i:3;s:11:\"RODDY, P. J\";i:4;s:13:\"SCHULTZ, H. J\";i:5;s:8:\"TA, Q. V\";i:6;s:11:\"TOMAI, M. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:55:\"Development of a topically active imiquimod formulation\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Informa Healthcare\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1080\/10837459908984222\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:55:\"Development of a topically active imiquimod formulation\";s:9:\"\u0000*\u0000jtitle\";s:41:\"Pharmaceutical development and technology\";s:9:\"\u0000*\u0000stitle\";s:19:\"Pharm. dev. technol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:1:\"4\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"35\";s:8:\"\u0000*\u0000epage\";s:2:\"43\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1083-7450\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"CHOLLET\";s:10:\"\u0000*\u0000aufirst\";s:4:\"J. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:18:\"JOZWIAKOWSKI, M. J\";i:1;s:12:\"PHARES, K. R\";i:2;s:12:\"REITER, M. J\";i:3;s:11:\"RODDY, P. J\";i:4;s:13:\"SCHULTZ, H. J\";i:5;s:8:\"TA, Q. V\";i:6;s:11:\"TOMAI, M. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:55:\"Development of a topically active imiquimod formulation\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Informa Healthcare\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1080\/10837459908984222\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:55:\"Development of a topically active imiquimod formulation\";s:9:\"\u0000*\u0000jtitle\";s:41:\"Pharmaceutical development and technology\";s:9:\"\u0000*\u0000stitle\";s:19:\"Pharm. dev. technol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:1:\"4\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"35\";s:8:\"\u0000*\u0000epage\";s:2:\"43\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1083-7450\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"CHOLLET\";s:10:\"\u0000*\u0000aufirst\";s:4:\"J. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:18:\"JOZWIAKOWSKI, M. J\";i:1;s:12:\"PHARES, K. R\";i:2;s:12:\"REITER, M. J\";i:3;s:11:\"RODDY, P. J\";i:4;s:13:\"SCHULTZ, H. J\";i:5;s:8:\"TA, Q. V\";i:6;s:11:\"TOMAI, M. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:55:\"Development of a topically active imiquimod formulation\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Informa Healthcare\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
